Figure 4.
Predose serum concentration-time and serum PD-time profiles for crizanlizumab. Mean and median predose serum concentration-time (A) and serum PD-time profiles (B) for crizanlizumab 5.0 and 7.5 mg/kg (PAS2 and PDS2, respectively).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.